Title:
持続放出型ラノラジン製剤
Document Type and Number:
Japanese Patent JP3745621
Kind Code:
B2
Abstract:
The present invention relates to the use of ranolazine for the preparation of a pharmaceutical composition for treating a human suffering from a cardiovascular disease, wherein the pharmaceutical composition maintains ranolazine plasma levels in the human of from about 550 to about 7500 ng base/ml for at least 24 hours. Furthermore, the present invention relates to a pharmaceutical composition comprising ranolazine, at least one pH dependent binder and at least one pH independent binder for treating a human suffering from a cardiovascular disease.
Inventors:
Wolf, Andrew A.
Baker, Fiona
Lang Ridge, John
Baker, Fiona
Lang Ridge, John
Application Number:
JP2000568494A
Publication Date:
February 15, 2006
Filing Date:
September 09, 1999
Export Citation:
Assignee:
CV THERAPEUTICS, INC.
SYNTEX(U.S.A.)INCORPORATED
SYNTEX(U.S.A.)INCORPORATED
International Classes:
A61K9/20; A61K31/495; A01N43/58; A01N43/60; A61K9/22; A61K9/28; A61K9/52; A61K31/50; A61K47/32; A61K47/34; A61K47/38; A61P9/00; A61P9/06; A61P9/10
Domestic Patent References:
| JP3048672A | ||||
| JP6199657A | ||||
| JP9188617A | ||||
| JP59219271A | ||||
| JP62252732A |
Attorney, Agent or Firm:
Hidekazu Miyoshi